☆ 4.6 Article

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

CELLS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer

Diego de Miguel-Perez et al.

Summary: Immune-checkpoint inhibitors are effective in treating lung cancer, but there is a need for better predictive biomarkers to identify patients who will benefit. This study found that high levels of TGF-beta in extracellular vesicles before treatment were a better predictor of response to ICIs and survival compared to circulating TGF-beta and tissue PD-L1.

CANCER (2023)

添加到收藏夹

Article Oncology

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Diego de Miguel-Perez et al.

Summary: This study evaluated the use of extracellular vesicle PD-L1 expression as a biomarker for predicting durable treatment response and survival in non-small cell lung cancer (NSCLC) patients receiving immune-checkpoint inhibitors (ICIs). The results showed that an increase in extracellular vesicle PD-L1 was observed in non-responders compared to responders and was an independent biomarker for shorter progression-free survival and overall survival. In contrast, tissue PD-L1 expression, the commonly used biomarker, was not predictive for durable response or survival.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tumor activated platelets induce vascular mimicry in mesenchymal stem cells and aid metastasis

Avishek Bhuniya et al.

Summary: The extent of cancer metastasis affects platelet activation in the tumor microenvironment. Activated platelets enhance the migration of mesenchymal stem cells (MSCs) in secondary metastatic sites, leading to the formation of vascular mimicry (VM). This VM phenomenon has been observed in various types of cancer and is associated with poor prognosis.

CYTOKINE (2022)

添加到收藏夹

Review Oncology

Platelet detection as a new liquid biopsy tool for human cancers

Maoshan Chen et al.

Summary: Platelets, as a biomarker, have wide applications in cancer screening and treatment. Through the interactions with cancer cells, platelets can transfer proteins and RNAs, affecting tumor growth and metastasis. The count, volume, and protein profiles of platelets can also be used for early cancer detection.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Engineering, Biomedical

Dissecting the effects of preconditioning with inflammatory cytokines and hypoxia on the angiogenic potential of mesenchymal stromal cell (MSC)-derived soluble proteins and extracellular vesicles (EVs)

Cansu Gorgun et al.

Summary: The research demonstrates that the MSC secretome is strongly modulated by concurrent stimulation with hypoxia and pro-inflammatory cytokines, which mimics the harsh environment at the injury site. The environmental variations strongly influence the angiogenic potential of different secretome fractions.

BIOMATERIALS (2021)

添加到收藏夹

Article Oncology

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC

Roy S. Herbst et al.

Summary: In patients with advanced NSCLC with PD-L1 TPS >= 50% and >= 1%, pembrolizumab continues to provide long-term benefit compared to docetaxel, with significant improvement in overall survival rates after 5 years. The findings confirm pembrolizumab as a standard-of-care treatment in the second-line or later setting.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

Clemens Hinterleitner et al.

Summary: This study demonstrates that platelet-derived PD-L1 can serve as a prognostic and predictive biomarker in non-small cell lung cancer patients, playing a role in tumor immune evasion and affecting T cell function. An algorithm was developed to calculate the adjusted PD-L1 payload of platelets (pPD-L1(Adj.)), which showed superior predictive ability for therapy response compared to standard histological PD-L1 quantification.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

So Yeon Oh et al.

Summary: The study revealed that high levels of sPD-L1 in cancer patients were associated with progressive disease and worse prognosis, as well as positively correlated with neutrophil to lymphocyte ratios and negatively correlated with lymphocyte proportions and total numbers.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies

Ryotaro Ohkuma et al.

Summary: The study investigated the clinical implications of soluble PD-1 levels in cancer patients treated with immune checkpoint inhibitors (ICIs). Findings showed that changes in sPD-1 levels may play a role in resistance to anti-PD-1 therapy, suggesting its potential as a predictive biomarker for response to ICI treatment in cancer patients.

BIOMEDICINES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Soluble B7-H3 in Ovarian Cancer and Its Predictive Value

O. Kovaleva et al.

Summary: The study revealed that increased plasma content of sB7-H3 in patients with epithelial ovarian cancer is associated with unfavorable prognosis of the disease, indicating its potential as a prognostic marker.

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

Angela Alama et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab

Carlo Genova et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Platelets and Platelet-Derived Extracellular Vesicles in Liver Physiology and Disease

Alexandre Balaphas et al.

HEPATOLOGY COMMUNICATIONS (2019)

添加到收藏夹

Article Oncology

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer

Yusuke Okuma et al.

CLINICAL LUNG CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Immunology

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

Flavia Castro et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Clinical significance of serum soluble B7-H3 in patients with osteosarcoma

Ling Wang et al.

CANCER CELL INTERNATIONAL (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Gang Chen et al.

NATURE (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma

Takeshi Azuma et al.

PLOS ONE (2018)

添加到收藏夹

Article Oncology

PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer

Kousaku Mimura et al.

CANCER SCIENCE (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer et al.

LANCET (2017)

添加到收藏夹

Article Oncology

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

Yusuke Okuma et al.

LUNG CANCER (2017)

添加到收藏夹

Review Oncology

New B7 Family Checkpoints in Human Cancers

Ling Ni et al.

MOLECULAR CANCER THERAPEUTICS (2017)

添加到收藏夹

Article Oncology

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes

Mehmet Altan et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Joseph L. Benci et al.

CELL (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Review Oncology

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Suzanne L. Topalian et al.

NATURE REVIEWS CANCER (2016)

添加到收藏夹

Article Oncology

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

K. Abiko et al.

BRITISH JOURNAL OF CANCER (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Oncology

B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look

Jenessa B. Smith et al.

GYNECOLOGIC ONCOLOGY (2014)

添加到收藏夹

Review Oncology

B7-H3-mediated tumor immunology: Friend or foe?

Ling Wang et al.

INTERNATIONAL JOURNAL OF CANCER (2014)

添加到收藏夹

Article Respiratory System

Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis

Sandra Gottschling et al.

EUROPEAN RESPIRATORY JOURNAL (2013)

添加到收藏夹

Article Oncology

The Two Faces of Interferon-γ in Cancer

M. Raza Zaidi et al.

CLINICAL CANCER RESEARCH (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses

Yosuke Kamimura et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)

添加到收藏夹

Article Medicine, General & Internal

Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data

Takeshi Azuma et al.

PLOS MEDICINE (2009)

添加到收藏夹

Article Oncology

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells

Paolo Carrega et al.

CANCER (2008)

添加到收藏夹

Article Immunology

Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum

Guangbo Zhang et al.

IMMUNOLOGY (2008)

添加到收藏夹

Review Oncology

The new B7s: Playing a pivotal role in tumor immunity

Dallas B. Flies et al.

JOURNAL OF IMMUNOTHERAPY (2007)

添加到收藏夹

Article Public, Environmental & Occupational Health

Estimating the relative risk in cohort studies and clinical trials of common outcomes

LA McNutt et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)

添加到收藏夹

Article Immunology

Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells

XB Wang et al.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)

添加到收藏夹

Article Immunology

B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production

AI Chapoval et al.

NATURE IMMUNOLOGY (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.